Company intelligence / Profile preview

IDX20

Brookline, Massachusetts, United Statesidx20.us ↗

Ownership: Private
Development stage: Commercial

Overview

IDX20 develops rapid, highly accurate diagnostic assays using recombinant molecules derived from immune cells of mammals exposed to pathogens. Their technology leverages proprietary electric and magnetic properties of nanoparticles for enhanced detection. Results are delivered in real time via a mobile app, enabling immediate public health responses[1][4].

No clinical trial results (as would be typical for therapeutics) are reported; the company’s products appear to be commercially available diagnostic tools[1].

Pipeline breadth cannot be precisely determined but the company describes comprehensive solutions for epidemic containment[1].

Therapeutic areas: Infectious Diseases
Modalities: Diagnostic assayRecombinant proteinNanoparticle
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on IDX20.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDX20.

Explore the full profile